These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28609648)

  • 1. When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers.
    Stavrinides V; Parker CC; Moore CM
    Cancer Treat Rev; 2017 Jul; 58():14-21. PubMed ID: 28609648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Surveillance for Prostate Cancer: How to Do It Right.
    Garisto JD; Klotz L
    Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostics of prostate cancer is changing.
    Sandeman K; Rannikko A; Kenttämies A; Mirtti T
    Duodecim; 2016; 132(24):2351-8. PubMed ID: 29199795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Active surveillance for low-risk prostate cancer].
    Herlemann A; Stief CG
    Urologe A; 2016 Feb; 55(2):269-81. PubMed ID: 26831055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Active surveillance for prostate cancer].
    Dariane C
    Prog Urol; 2015 Nov; 25(14):884-7. PubMed ID: 26184043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
    Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
    Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
    van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
    Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Surveillance for Intermediate Risk Prostate Cancer.
    Klotz L
    Curr Urol Rep; 2017 Aug; 18(10):80. PubMed ID: 28801885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining 'progression' and triggers for curative intervention during active surveillance.
    Klotz L
    Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?
    Tomašković I
    Acta Clin Croat; 2015 Sep; 54(3):337-44. PubMed ID: 26666105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.